基本信息
views: 294
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
For 42 years, Dr. Levine has conducted Phase 1, 2, 3, and 4 clinical trials to evaluate the safety, immunogenicity, and efficacy of a wide array of vaccines; served as a clinician in vaccine testing for both adults and children; designed and supervised domestic and international epidemiologic studies; overseen research activities in the laboratory; and supervised development of diagnostic assays for use in developing countries and subsequent testing in field trials. His laboratory research has focused on the construction and characterization of attenuated strains of Salmonella Typhi, S. Paratyphi A, non-typhoidal Salmonella serovars, and Shigella to serve as live oral vaccines and as live vectors for the expression of foreign antigens. Multiple constructs have progressed from animal models to human trials.
Dr. Levine has designed and supervised large-scale, randomized, controlled field trials that investigated the efficacy of live oral typhoid vaccine Ty21a, which led to its licensure by the US Food and Drug Administration (FDA). Post-licensure work with Haemophilus influenzae type b conjugate vaccine led to early introductions into the routine infant immunization schedule in Chile (1996) and Mali, West Africa (2005). After years of challenge trials and an effective clinical trial, the single-dose oral cholera vaccine, Vaxchora, was approved for licensure by the FDA in 2016.
Dr. Levine has designed and supervised large-scale, randomized, controlled field trials that investigated the efficacy of live oral typhoid vaccine Ty21a, which led to its licensure by the US Food and Drug Administration (FDA). Post-licensure work with Haemophilus influenzae type b conjugate vaccine led to early introductions into the routine infant immunization schedule in Chile (1996) and Mali, West Africa (2005). After years of challenge trials and an effective clinical trial, the single-dose oral cholera vaccine, Vaxchora, was approved for licensure by the FDA in 2016.
Research Interests
Papers共 768 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
FRONTIERS IN IMMUNOLOGY (2024): 1334762-1334762
Scientific reportsno. 1 (2024): 13871-13871
The Journal of infectious diseases (2024)
MICROBIAL GENOMICSno. 3 (2024)
NEJM Evidenceno. 3 (2023): EVIDctcs2200301-EVIDctcs2200301
The journal of infectious diseases (Online University of Chicago Press)/The Journal of infectious diseases (2023)
Current Developments in Nutrition (2023): 101007-101007
The Lancet microbeno. 4 (2023): e228-e235
Load More
Author Statistics
#Papers: 772
#Citation: 52756
H-Index: 115
G-Index: 201
Sociability: 8
Diversity: 4
Activity: 69
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn